Turkish President Recep Tayyip Erdogan (C) visits the KeyVac Vaccine Production Center in Ankara, Türkiye, on Oct. 31, 2023. (Xinhua/Li Zhenbei)
BEIJING, May 31 (Xinhua) -- Chinese biopharmaceutical company Sinovac Biotech Ltd. (Sinovac) announced on Thursday that KeyVac, a joint venture (JV) between the company and Türkiye's Alagoz Holding, had won the bid for a project on the long-term supply of hepatitis A and chickenpox vaccines to Türkiye.
The winning of the bid testifies Sinovac's vaccine products, services and technical capabilities have been recognized and trusted by the government and people of Türkiye. It also marks an important step forward for the company in advancing international cooperation, Yang Guang, chief business officer with Sinovac said on Thursday in Beijing.
Sinovac has supplied nearly 94 million doses of vaccines to Türkiye since 2020, including COVID-19 vaccines, hepatitis A vaccines, influenza vaccines and chickenpox vaccines.
The company and its Turkish partner jointly established KeyVac in the Turkish capital of Ankara in October 2021. The KeyVac vaccine production center, with a total investment of 100 million U.S. dollars, has an annual production capacity of 30 million doses of vaccines. (Edited by Su Dan with Xinhua Silk Road, sudan@xinhua.org)
A single purchase
